March 2026. Volume 22. Number 1

Hydroxychloroquine for prophylaxis of congenital atrioventricular block: the most recomended, but with little evidence

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Agarwal A, Skoutelis N, Zhou Y, Kawanami R, Charras A, Occhigrossi F, et al. Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review. Arch Dis Child. 2025;110:556-65.

Reviewers: Oltra Benavent M1, Blanco Rodríguez C2.
1Sección de Patología Infecciosa Infantil. Hospital Universitari i Politècnic La Fe. Valencia. España.
2Pediatra. CS Sanchinarro. Madrid. España.
Correspondence: Manuel Oltra Benavent . Email: oltra.benavent@gmail.com
Reception date: 13/01/2026
Acceptance date: 21/01/2026
Publication date: 28/01/2026

Abstract

Authors ́ conclusions: hydroxychloroquine, treatment showed the greatest evidence for preventing congenital atrioventricular block, although this was obtained from studies with a high risk of bias and imprecision.

Reviewers ́ commentary: prophylactic treatment with hydroxychloroquine in pregnant women with positive anti-Ro/La for autoimmune-mediated congenital heart block presents limited evidence. Given the low toxicity observed and the severity of the effect without treatment, the use of chloroquine may be justified until higher quality studies are available.

How to cite this article

Oltra Benavent M, Blanco Rodríguez C. Hidroxicloroquina para profilaxis de bloqueo auriculoventricular congénito: el fármaco más recomendado, pero con escasa evidencia. Evid Pediatr. 2026;22:5.

AVC | Critically appraised articles

Agarwal A, Skoutelis N, Zhou Y, Kawanami R, Charras A, Occhigrossi F, et al. Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review. Arch Dis Child. 2025;110:556-65.

Reviewers: Oltra Benavent M1, Blanco Rodríguez C2.
1Sección de Patología Infecciosa Infantil. Hospital Universitari i Politècnic La Fe. Valencia. España.
2Pediatra. CS Sanchinarro. Madrid. España.
Correspondence: Manuel Oltra Benavent . Email: oltra.benavent@gmail.com
Reception date: 13/01/2026
Acceptance date: 21/01/2026
Publication date: 28/01/2026

How to cite this article

Oltra Benavent M, Blanco Rodríguez C. Hidroxicloroquina para profilaxis de bloqueo auriculoventricular congénito: el fármaco más recomendado, pero con escasa evidencia. Evid Pediatr. 2026;22:5.

28/01/2026

Linked Comment

Methodological note